Company profile for NFL Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NFL Biosciences botanical pharmaceutical agent was initially developed by the Pasteur Institute in France as an allergenic extract used for the desensitization of tobacco factories' workers suffering from allergies to the manipulation of tobacco leaves. Commercialized by Stallergenes until 2004 the allergenic extract had been repositioned over the previous ten years as a smoking cessation aid by an anesthesiologist and mesoth...
NFL Biosciences botanical pharmaceutical agent was initially developed by the Pasteur Institute in France as an allergenic extract used for the desensitization of tobacco factories' workers suffering from allergies to the manipulation of tobacco leaves. Commercialized by Stallergenes until 2004 the allergenic extract had been repositioned over the previous ten years as a smoking cessation aid by an anesthesiologist and mesotherapy practitioner in the Clinique du Parc, Orange, France, Dr. Jean-Pierre Nicolas. Today, in 2021, NFL-101 is ready to enter Phase II/III clinical study

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
199 rue Hélène Boucher 34170 Castelnau-Le-Lez
Telephone
Telephone
+33.4.11.93.76.67
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-10-20/nfl-biosciences-outlines-its-development-plan-for-nfl-101-in-smoking-cessation-following-receipt-of

PHARMIWEB
20 Oct 2025

https://www.globenewswire.com/news-release/2023/07/18/2706090/0/en/Nfl-Biosciences-Patent-Application-Filed-in-the-United-States-for-Reducing-Alcohol-Consumption-With-Nfl-301-Preparation-of-a-Pre-Ind-Application-Submission-With-the-Fda.html

GLOBENEWSWIRE
18 Jul 2023

https://www.globenewswire.com/news-release/2023/07/05/2699806/0/en/NFL-BIOSCIENCES-CO-FOUNDER-SHAREHOLDER-FURTHER-STRENGTHENS-HIS-POSITION-BY-EXERCISING-BSPCE-WARRANTS.html

GLOBENEWSWIRE
05 Jul 2023

https://www.globenewswire.com/news-release/2023/06/29/2697240/0/en/NFL-BIOSCIENCES-GB-HOLDING-TAKES-A-STAKE-IN-THE-COMPANY-S-CAPITAL-UPON-THE-EXERCISE-OF-SHARE-SUBSCRIPTION-WARRANTS-AND-PAYMENT-OF-0-5M-AND-ALSO-COMMITS-TO-A-LOCK-UP.html

GLOBENEWSWIRE
29 Jun 2023

https://www.globenewswire.com/news-release/2023/06/28/2696451/0/en/NFL-BIOSCIENCES-RESULTS-OF-THE-COMBINED-GENERAL-MEETING-OF-JUNE-27-2023.html

GLOBENEWSWIRE
28 Jun 2023

https://www.globenewswire.com/news-release/2023/06/21/2692359/0/en/NFL-BIOSCIENCES-Approval-for-its-patent-to-be-granted-on-NFL-101-in-Europe-and-approval-of-the-clinical-development-plan-for-NFL-101-by-the-EMA.html

GLOBENEWSWIRE
21 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty